Prophylaxis of chemotherapy-induced neutropenia with lipegfilgrastim in patients with lung cancer: final results from the non-interventional study NADIR
Christian Geßner, Karin Potthoff(Heidelberg University), Sina Grebhardt(Iomedico (Germany)), Nikolaj Frost(Humboldt-Universität zu Berlin), Matthias Groschek(Aachen Institute for Nuclear Training), H. Schulz(Uni Research (Norway)), Thomas Fietz(Praxis für Hämatologie und Onkologie), Beate Niemeier(Iomedico (Germany)), Joachim Hipp(Teva Pharmaceuticals (Germany)), H. Eschenburg(Heidelberg University), Johanna Harde(Iomedico (Germany)), Albrecht Kretzschmar(Roche (Switzerland)), Andreas Lück, Christiane D. Matillon(Iomedico (Germany)), Christoph Losem, Rudolf Weide
Cited by 2
Related Papers
Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs
|Cancer Treatment Reviews|2016|616
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
|European Journal of Cancer|2011|615